Novel Experimental COVID-19 Therapies Affecting Host Response

Inclusion criteria

   1. Hospitalized for COVID-19

   2. ≥18 years of age

   3. SARS-CoV-2 infection, documented by:

      1. a nucleic acid test (NAT) or equivalent testing within 3 days prior to
      randomization OR

      2. documented by NAT or equivalent testing more than 3 days prior to randomization
      AND progressive disease suggestive of ongoing SARS-CoV-2 infection per the
      responsible investigator (For non-NAT tests, only those deemed with equivalent
      specificity to NAT by the protocol team will be allowed. A central list of
      allowed non- NAT tests is maintained in Appendix E. Appendix E. Non-NAT Tests
      Deemed with Equivalent Specificity to NAT by the Protocol Team).

   4. Hypoxemia, defined as SpO2 <92% on room air, new receipt of supplemental oxygen to
   maintain SpO2 ≥92%, or increased supplemental oxygen to maintain SpO2 ≥92% for a
   patient on chronic oxygen therapy

   5. Symptoms or signs of acute COVID-19, defined as one or more of the following:

      1. cough

      2. reported or documented body temperature of 100.4 degrees Fahrenheit or greater

      3. shortness of breath

      4. chest pain

      5. infiltrates on chest imaging (x-ray, CT scan, lung ultrasound)

Exclusion criteria

   1. Onset of COVID-19 symptom fulfilling inclusion criterion #5 >14 days prior to
   randomization

   2. Hospitalized with hypoxemia (as defined in inclusion #4) for >72 hours prior to
   randomization (the 72-hour window for randomization begins when the patient first
   meets the hypoxemia inclusion criteria after hospital admission)

   3. Pregnancy

   4. Breastfeeding

   5. Prisoners

   6. End-stage renal disease (ESRD) on dialysis

   7. Patient undergoing comfort care measures only such that treatment focuses on
   end-of-life symptom management over prolongation of life.

   8. The treating clinician expects inability to participate in study procedures or
   participation would not be in the best interests of the patient

   9. Known allergy/hypersensitivity to IMP or its excipients

The following exclusion criteria differ from the master protocol criteria:

TXA127-specific exclusion criteria(4/20/2022 Closed to Accrual):

   1. Patient unable to participate or declines participation in the TXA127/Ang(1-7) arm.

   2. History of sensitivity (including angioedema) or allergic reaction to medication
   targeting the RAAS system including study medications or other allergy in the opinion
   of the investigator that contraindicates participation (not applicable to fostamatinib
   arm)

   3. Hemodynamic instability - defined as MAP < 65 mmHg at time of randomization confirmed
   on two measurements 5 minutes apart OR vasopressors at or above norepinephrine
   equivalent of 0.1 mcg/kg/min in prior 4 hours to maintain MAP > 65 mmHg.

   4. Known severe renal artery stenosis.

   5. Known significant left ventricular outflow obstruction, such as obstructive
   hypertrophic cardiomyopathy or severe aortic or mitral stenosis.

   6. Randomized in another trial evaluating RAAS modulation in the prior 30 days

TRV027-specific exclusion criteria (4/20/2022 Closed to Accrual):

   1. Participants on ARBs will be excluded from this study arm.

   2. Patient unable to participate or declines participation in the TRV027 arm.

   3. History of sensitivity (including angioedema) or allergic reaction to medication
   targeting the RAAS system including study medications or other allergy in the opinion
   of the investigator that contraindicates participation (not applicable to fostamatinib
   arm)

   4. Hemodynamic instability - defined as MAP < 65 mmHg at time of randomization confirmed
   on two measurements 5 minutes apart OR vasopressors at or above norepinephrine
   equivalent of 0.1 mcg/kg/min in prior 4 hours to maintain MAP > 65 mmHg.

   5. Known severe renal artery stenosis.

   6. Known significant left ventricular outflow obstruction, such as obstructive
   hypertrophic cardiomyopathy or severe aortic or mitral stenosis.

   7. Randomized in another trial evaluating RAAS modulation in the prior 30 days

Fostamatinib specific exclusion criteria:

The following exclusion criteria differ from the master protocol criteria:

1. Randomized in another trial evaluating fostamatinib in the prior 30 days

Study arm exclusion criteria measured within 24 hours prior to randomization:

   1. AST or ALT ≥ 5 × upper limit of normal (ULN) or ALT or AST ≥ 3 × ULN and total
   bilirubin ≥ 2 × ULN

   2. SBP > 160 mmHg or DBP > 100 mmHg at the time of screening and randomization

   3. ANC < 1000/mL

   4. Patient is anticipated to require a strong CYP3A inhibitor (Atazanavir, Certinib,
   Clarithromycin, Cobicistat and cobicistat-containing coformulations,
   Idelalisib,Indinavir, Itraconazole, Ketoconazole, Levoketoconazole, Lonafarnib,
   Lopinavir, Mifeprostone, Mibefradil, Nefazodone, Nelfinavir,
   Ombitasvir-paritaprevir-ritonavir plus dasabuvir, Posaconazole, Ribociclib Ritonavir,
   Saquinavir, Telithromycin, Troleandomycin, Tucatinib, Voriconazole) from randomization
   to 21 days post-randomization. For a full list of CYP3A4 substrates, please reference
   this regularly updated list: https://drug-interactions.medicine.iu.edu/MainTable.aspx.

   5. Patient unable to participate or declines participation in the fostamatinib arm.